Newsroom

Led by Biomunex alongside Institut Curie and GTP Bioways, with a total budget of €5.6 million, BiXAb5 non-conventional T cell redirection project seeks to create breakthrough immunotherapy approach to cancer treatment based on bispecific antibodies

German-based startup attracts venture funding from leading European VC firms to address ‘Agitation/Aggression’ in Alzheimer’s disease

• Strong first closing confirms relevance of AFB’s unique early-stage investment strategy; aiming to create, develop and finance promising European life sciences startups in innovative therapeutics

• Since 2017, AFB’s €68M ($80M) first fund – Advent France Biotechnology Seed-Fund I – has successfully financed 15 startups in France, Spain, Belgium and Ireland

Venture capital firm Advent France Biotechnology led fundraising, alongside Crédit Mutuel Innovation and Pierre Fabre

Co-founded by AFB and leading cancer institutes Gustave Roussy and Institut Curie, startup will use funding to prepare essential preclinical work to identify first oncology program to develop

Les fonds apportés vont permettre à la nouvelle start-up de développer une approche thérapeutique innovante pour les patients atteints de maladies inflammatoires chroniques